Summary: Researchers have discovered an unexpected connection between a well-known cancer signaling axis and the protective blood-brain and blood-retina barriers. The study shows that the tumor-suppressor protein p53 can weaken Norrin/Frizzled4 signaling—an essential pathway for vascular stability in the central nervous system—largely by reducing levels of the condensin I complex component NCAPH. These results indicate that therapies designed to raise p53, such as MDM2 inhibitors, could unintentionally compromise vascular barrier integrity in the brain and retina.
The work, led by investigators at the University of Minnesota Medical School and published in Science Signaling, identifies NCAPH as a candidate disease gene for inherited retinal vascular disorders and pinpoints a molecular mechanism linking p53 signaling to endothelial barrier regulation.
Key Facts:
- Barrier vulnerability: Elevated p53 reduces Norrin/Frizzled4 signaling in endothelial cells, undermining blood-brain and blood-retina barrier function.
- Therapeutic risk: MDM2 inhibitors that increase p53 abundance may carry the unintended consequence of promoting neuroinflammation, vascular leakage, or dysregulated transport across blood-CNS barriers.
- Candidate disease gene: NCAPH emerges as a likely downstream effector of p53 in endothelial cells and a potential contributor to familial exudative vitreoretinopathy (FEVR) and related vascular disorders.
Source: University of Minnesota
Overview of the discovery
A University of Minnesota Medical School team has revealed that the MDM2–p53 signaling axis, long studied for its tumor-suppressive role, also affects retinal and brain vasculature through modulation of the Norrin/Frizzled4 pathway. Blood–CNS barriers regulate the movement of nutrients, hormones and waste between the bloodstream and the central nervous system and prevent swelling and inflammation in retinal and brain tissue. Proper Norrin/Frizzled4 signaling in endothelial cells is essential for establishing and maintaining these barriers.
Until now, a direct connection between p53 regulation and Norrin-driven signaling in the vasculature had not been recognized. Harald Junge, PhD, an associate professor at the University of Minnesota Medical School, summarizes the importance: these findings reveal a previously unappreciated link between the cellular stress response governed by p53 and the signaling that maintains blood–CNS barrier integrity.
Using a combination of transcriptomic profiling, cell-based assays and mouse genetics, the investigators demonstrated that endothelial cell–specific loss of Mdm2 reduced Norrin/Frizzled4 pathway activity, lowered endothelial proliferation and impaired retinal angiogenesis. These vascular and barrier defects were largely reversed when Trp53 was deleted concurrently, indicating that the effects of Mdm2 loss are mediated through increased p53 activity.
Mechanistically, the study links p53-driven reduction of NCAPH expression with diminished Norrin/Frizzled4 signaling and suppressed endothelial proliferation. This provides a plausible molecular route by which increased p53 activity can compromise barrier function in the CNS vasculature.
Clinical and research implications
Because MDM2 inhibitors are being developed and tested to elevate p53 as a cancer therapy, these findings raise an important caution: boosting p53 could unintentionally impair blood–CNS barrier function and promote neuroinflammatory or edematous responses in susceptible patients. The work supports the need to monitor barrier integrity and neurovascular outcomes in clinical trials of MDM2-targeted agents.
The identification of NCAPH as a downstream p53 effector in endothelial cells also highlights a candidate gene for familial exudative vitreoretinopathy (FEVR), a rare hereditary disorder caused by defects in Norrin signaling and retinal vascular development. Further study of NCAPH in endothelial biology and human genetics could clarify its role in inherited and acquired vascular pathologies.
Funding: This research was supported by grants from the National Eye Institute and the National Institutes of Health [R01EY024261, R01EY033316 and 1R21DA056728-01A1].
About this brain cancer research news
Author: Alexandra Smith
Source: University of Minnesota
Contact: Alexandra Smith – University of Minnesota
Image credit: Neuroscience News
Original Research: Open access. “The MDM2-p53 axis regulates norrin/frizzled4 signaling and blood-CNS barrier function” by Harald Junge et al., published in Science Signaling.
Abstract
The MDM2-p53 axis regulates norrin/frizzled4 signaling and blood-CNS barrier function
Norrin-induced activation of β-catenin–dependent signaling through the receptor Frizzled4 in endothelial cells is essential for establishing and maintaining blood–CNS barrier function. The authors investigated how this pathway is modulated under stress or disease conditions, focusing on p53 because elevated p53 levels in endothelial cells are associated with leaky CNS vessels in conditions such as type 2 diabetes.
Combining transcriptomics, cell-based assays and mouse genetic models, the study uncovers interplay between p53, its negative regulator MDM2, and Norrin/Frizzled4 signaling. Endothelial cell–specific deletion of Mdm2 led to decreased Norrin/Frizzled4 signaling, reduced endothelial proliferation and retinal angiogenesis, and disrupted blood–retina barrier function. These defects were largely restored by concurrent deletion of Trp53.
Decreased Norrin/Frizzled4 signaling and suppressed endothelial proliferation in response to p53 correlated with reduced expression of NCAPH, a component of the condensin I complex. The findings identify NCAPH as a regulator of Norrin/Frizzled4 signaling and suggest that clinical use of MDM2 inhibitors could impair blood–CNS barrier function. Additionally, NCAPH may act as a downstream effector of p53 in endothelial cells and represents a candidate gene for familial exudative vitreoretinopathy, a disease caused by defects in Norrin signaling.